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A B S T R A C T
Background
Cystic fibrosis (CF) is a genetic disorder with multiorgan effects. In a subgroup with pancreatic insufficiency malabsorption of the
fat soluble vitamins (A, D, E, K) may occur. Vitamin D is involved in calcium homeostasis and bone mineralisation and may have
extraskeletal effects. This review examines the evidence for vitamin D supplementation in CF.
Objectives
To assess the effects of vitamin D supplementation on the frequency of vitamin D deficiency, respiratory outcomes and vitamin D
toxicity in the CF population.
Search methods
We searched the Cochrane CF and Genetic Disorders Group Trials Register comprising references identified from comprehensive
electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
Most recent search: 14 March 2011.
Selection criteria
Randomised and quasi-randomised controlled trials of vitaminD supplementation compared to placebo in theCF population regardless
of exocrine pancreatic function.
Data collection and analysis
Both authors independently assessed the ’risk of bias’ of each included trial and extracted outcome data (frompublished trial information)
for assessment of bone mineralization, growth and nutritional status, frequency of vitamin D deficiency, respiratory status, quality of
life and adverse events.
Main results
Three studies are included, although only data from two were available (41 adults and children with CF). One of these studies compared
supplemental 800 international units (IU) vitamin D and placebo for 12 months in 30 osteopenic pancreatic insufficient adults; both
groups continued 900 IU vitamin D daily. The other (abstract only) compared supplemental 1g calcium alone, 1600 IU vitamin
D alone, 1600 IU vitamin D and 1g calcium and placebo in a double-blind randomised cross-over trial; only 11 children (vitamin
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D and placebo groups) after six-months supplementation are included; inclusion criteria, pancreatic sufficiency or disease status of
participants are not defined. There were no significant differences in primary or secondary outcomes in either study. The studies are
not directly comparable due to differences in supplementation, outcome reporting and possibly participant characteristics (eg severity
of lung disease, growth and nutrition, pancreatic sufficiency). There were no adverse events in either study. The third study (abstract
only) compared daily calcitriol (0.25 or 0.5 micrograms) with placebo in pancreatic insufficient children and young adults, only pre-
intervention data were available.
Authors’ conclusions
There is no evidence of benefit or harm in the limited number of small-sized published trials. Adherence to relevant CF guidelines on
vitamin D should be considered until further evidence is available.
P L A I N L A N G U A G E S U M M A R Y
The use of regular vitamin D preparations for children and adults with cystic fibrosis
Cystic fibrosis with pancreatic insufficiency can cause vitamins, such as vitamin D, to be inadequately absorbed leading to vitamin
deficiencies. Lack of vitamin D (vitamin D deficiency) can cause specific problems such as bone deformity and bone fractures. It can
also be associated with poorer general and respiratory health. Thus, people with cystic fibrosis are usually given regular vitamin D
preparations from a very young age. However, excess vitamin D can also cause respiratory problems and problems with high calcium
levels. The review contains three trials, but we could only extract data from two trials. We found no evidence to show whether giving
vitamin D regularly to people with cystic fibrosis is beneficial or not. The authors are unable to draw any conclusions regarding the
routine administration of Vitamin D supplements and recommend that until further evidence is available, local guidelines are followed
regarding this practice.
B A C K G R O U N D
Please note: a glossary of medical terms used in this review is
available in the appendices (Appendix 1).
Description of the condition
Cystic fibrosis (CF) is a genetic disorder that affects multiple or-
gans. The dominant symptoms of CF are that of the respiratory
and gastrointestinal (GI) systems (Wagener 2003). In a subgroup
of people with CF, the GI system, liver dysfunction, intestinal ob-
struction and exocrine pancreatic insufficiency are the major is-
sues. Pancreatic insufficiency affects up to 90% of people with CF,
whereby fat malabsorption occurs and pancreatic enzyme replace-
ment is required to prevent steatorrhoea and malnutrition (Dodge
2006). Fat soluble vitamins (A, D, E and K) are co-absorbed with
fat and thus deficiency of these vitamins may occur. European and
US guidelines recommend routine supplementation of these vita-
mins (Borowitz 2002; Sinaasappel 2002).
Vitamin D with parathyroid hormone (PTH) regulates serum
calcium and phosphate, maintaining adequate concentrations for
bone mineralization (Dimitri 2007; Holick 2007). Vitamin D de-
ficiency may present as symptomatic hypocalcaemia with tetany,
seizures or myopathy during early childhood, particularly in ex-
clusively breast-fed infants (Dimitri 2007; Wharton 2003) or as a
range of bone deformities (rickets, kypho-scoliosis) or other effects
such as delayed closure of anterior fontanelle, dentition problems
(delayed eruption of teeth and enamel hypoplasia) (Dimitri 2007;
Joiner 2000; Wharton 2003). Radiological changes of rickets in-
clude metaphyseal widening with cupping, splaying and fraying
(Dimitri 2007; Joiner 2000;Wharton2003).Generalised osteope-
nia may be an incidental X-ray finding of vitamin D deficiency in
an asymptomatic child (Joiner 2000). Vitamin D deficiency after
completion of skeletal growth or growth plate fusion causes osteo-
malacia without skeletal deformity due to unmineralised osteoid
replacing mineralised bone as part of normal bony remodeling; X-
rays demonstrate generalised osteopenia (Holick 2007). This bone
is more likely to fracture with poor healing (Holick 2007). Dif-
fuse bone pain accompanies osteomalacia in some adults (Holick
2007).
Vitamin D may also have extra-skeletal effects. Epidemiological
studies have also described a link between hypovitaminosis D and
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lung function (Black 2005); and plausible biological reasons in-
clude the effect of vitamin D on immunity and oxidative stress
(Wright 2005). However, excessive high doses of vitamin D can
also cause problems, albeit this rarely occurs. The effects of vi-
tamin D toxicity are generally non-specific and include nausea,
vomiting, poor appetite, constipation, weakness, and weight loss
(Chesney 1989;NIH2007). It can also cause hypercalcaemia lead-
ing to confusion, arrhythmia, and calcinosis (Chesney 1989; NIH
2007). As ultraviolet B radiation exposure results in the produc-
tion of vitamin D3, vitamin D levels are likely seasonal.
Description of the intervention
Different vitamin D preparations are available; the D2 prepara-
tion has been the main form given and available as a pharmaceuti-
cal preparation. However, both vitamins D2 and D3 are available
as supplementations and may vary in its efficacy for maintaining
serum concentrations of 25 (OH) D. These are prepared by dif-
ferent methods and occur naturally in different foods.
How the intervention might work
Both forms of vitamin D, when ingested, undergo metabolism in
the liver to form 25-hydroxyvitamin D (25 (OH) D) and in the
kidneys to form 1.25-dihydroxyvitamin D (Holick 2008). Also
vitamins D2 and D3 are equally efficacious in maintaining serum
concentrations of 25 (OH) D (Holick 2008).
Why it is important to do this review
The UKCF Trust recommends dietary advice and vitamin D sup-
plementation tomaintain 25 (OH) vitamin D levels in the normal
range of 30 to 60ng/ml for all individuals with pancreatic insuf-
ficiency (UK CF Trust 2007). Recommended starting doses vary
with age (UK CF Trust 2007). The USA Cystic Fibrosis Founda-
tion consensus panel recommends vitamin D supplementation to
maintain 25 (OH) vitamin D levels in the normal range of 30 to
60ng/ml (Aris 2005). The vitamin D preparation used and dosing
varies with age and treatment response (Aris 2005).
Deficiencies may occur from the disease process of CF and insuf-
ficient supplementation. Also vitamin D deficiency is increasingly
reported even in people without medical risk factors of vitamin
D deficiency. Nevertheless vitamin toxicity may also occur from
excess supplements. Vitamin D deficiency may lead to specific
symptoms and signs, as well as to other nutritional issues, and in-
fluence the general well-being and respiratory status (Dodge 2006;
Sethuraman 2006). A Cochrane Systematic Review of vitamin A
supplementation has already been published (O’Neil 2007). Vita-
min E andK supplementation will be addressed in other Cochrane
Reviews. This review will evaluate vitamin D supplementation.
O B J E C T I V E S
To determine if vitamin D supplementation in children and adults
with CF:
1. reduces the frequency of vitamin D deficiency disorders;
2. improves general and respiratory outcomes;
3. increases the frequency of vitamin D toxicity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised (RCTs) and quasi-randomised trials (controlled clin-
ical trials).
Types of participants
Children or adults with CF (defined by sweat tests or genetic
testing), with and without pancreatic insufficiency.
Types of interventions
All preparations of oral vitamin D used as a supplement compared
to placebo or no supplementation at any dose and for any du-
ration. Any preparation containing supplemental vitamin D was
included.
Types of outcome measures
Primary outcomes
1. Bone mineral density or Vitamin D specific deficiency
outcomes
i) osteopenia (defined on dual energy X-ray
absorptiometry (DXA) scans as T score between -1.0 and -2.5
standard deviations (SD) compared to a reference population
(World Health Organization 1994)
ii) osteoporosis (defined on DXA scans as T score less
than or equal to - 2.5 SD compared to a reference population
(World Health Organization 1994)
iii) severe osteoporosis (defined on DXA scans as T score
less than or equal to - 2.5 SD and with one or more fragility
fractures compared to a reference population (World Health
Organization 1994)
2. Growth and nutritional status (weight Z score)
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Secondary outcomes
1. Other vitamin D related deficiency disorders
i) fractures
ii) tetany
iii) rickets
iv) other radiological abnormality
v) measured levels of calcium and vitamin D (25-
hydroxyvitamin D (25 (OH) D) or 1.25-dihydroxyvitamin D
(1.25 (OH) D))
2. Respiratory outcomes
i) bronchiectasis severity control (e.g. QoL, cough diary,
Likert scale, visual analogue scale, level of interference of cough)
ii) lung function indices (spirometry e.g. FEV1, FVC)
iii) proportions of participants who had respiratory
exacerbations or hospitalisations or both
iv) total number of hospitalised days
v) other objective indices (e.g. airway markers of
inflammation)
3. Quality of life
4. Adverse events including vitamin D toxicity (e.g. vomiting,
loss of appetite, arrhythmia, confusion)
5. Parathyroid hormone levels
Search methods for identification of studies
Electronic searches
Relevant trials from theGroup’s Cystic Fibrosis Trials Register were
identified using the term ’vitamin D’.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(Clinical Trials) (updated each new issue ofThe Cochrane Library),
quarterly searches of MEDLINE, a search of EMBASE to 1995
and the prospective handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work is
identified by searching the abstract books of three major cystic
fibrosis conferences: the International Cystic Fibrosis Conference;
the European Cystic Fibrosis Conference and theNorth American
Cystic Fibrosis Conference. For full details of all searching activi-
ties for the register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group Module.
Date of the latest search: 14 March 2011.
Searching other resources
We scanned the references in the papers of the included studies
for further relevant papers.
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, both authors independently
reviewed results of the literature searches, identifying relevant stud-
ies according to the inclusion criteria for further assessment. From
these studies, the same two authors independently examined the
papers in further detail to select studies for inclusion using the
stated criteria. There was no disagreement between authors. It was
planned that any disagreement would have been settled by discus-
sion and consensus would have been achieved.
Data extraction and management
The authors reviewed studies that satisfied the inclusion criteria for
the review and recorded the following information, where avail-
able:
• study setting;
• year of study;
• source of funding;
• participant recruitment details (including number of
eligible participants);
• season;
• latitude where study was conducted;
• parathyroid hormone;
• trial inclusion and exclusion criteria;
• randomisation and allocation concealment method;
• numbers of participants randomised;
• blinding (masking) of participants, care providers and
outcome assessors;
• dose and type of intervention;
• duration of therapy;
• co-interventions;
• numbers of participants not followed up;
• reasons for withdrawals from study protocol (clinical, side
effects, refusal and other);
• side effects of therapy;
• whether intention-to-treat analyses were possible.
The authors extracted data on the outcomes described above and
were evaluated based on
1. short term (12 months or less), and
2. medium to long term (over one year)
We planned to extract data relevant for outcomes at one month,
up to three months, up to six months, up to twelve months and
annually thereafter. We planned to consider including outcome
data of differing time periods. The duration of included studies
ranged from nine to twelve months, thus this review reports only
short term outcomes (up to twelve months).
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Assessment of risk of bias in included studies
In order to assess the risk of bias for each of the included studies, the
two review authors independently assessed the quality of included
studies according to theCochrane risk of bias tool (Higgins 2011).
Allocation concealment
Authors assessed allocation concealment in each study as follows:
1. Low risk of bias, if the allocation of participants involved a
central independent unit, on-site locked computer, identically
appearing numbered drug bottles or containers prepared by an
independent pharmacist or investigator, or sealed opaque
envelopes;
2. Unclear risk of bias, if the method used to conceal the
allocation was not described;
3. High risk of bias, if the allocation sequence was known to
the investigators who assigned participants or if the study was
quasi-randomised.
Generation of the allocation sequence
Authors graded each study for generation of allocation sequence
as follows:
1. Low risk of bias, if methods of randomisation included use
of a random number table, computer-generated lists or similar
methods;
2. Unclear risk of bias, if the trial was described as
randomised, but no description of the methods used to allocate
participants to treatment group was described;
3. High risk of bias, if methods of randomisation included
alternation; the use of case record numbers, dates of birth or day
of the week, and any procedure that is entirely transparent before
allocation.
Blinding (or masking)
Authors graded each study for blinding as follows:
1. blinding of clinician (person delivering treatment) to
treatment allocation;
2. blinding of participant to treatment allocation;
3. blinding of outcome assessor to treatment allocation.
Themore people blinded to an intervention, the lower the authors
judged the risk of bias to be.
Follow up
Authors graded each study as to whether numbers of and reasons
for dropouts and withdrawals in all intervention groups were de-
scribed; or if it was specified that there were no dropouts or with-
drawals.
We have reported on whether the investigators performed a sam-
ple-size calculation and if they used an intention-to-treat (ITT)
analysis. The risk of bias is higher for lower follow-up rates.
Selective outcome reporting (or reporting bias)
Authors graded each study for selective outcome reporting based
on all available results as follows:
1. Low risk of selective outcome reporting if all defined
outcomes for each study participant were reported;
2. Unclear risk of selective outcome reporting if it study
authors did not provide evidence of or report results for all
defined outcomes in study participants;
3. High risk of selective outcome reporting if incomplete
reporting or intention to report results of defined outcomes for
all enrolled participants.
Measures of treatment effect
The authors included the results from studies meeting the inclu-
sion criteria and which reported any of the outcomes of interest
in the subsequent meta-analyses.
For dichotomous outcome variables of each individual study, we
planned to calculate the odds ratio (OR) using a modified ITT
analysis, i.e. if ITT analysis was not used by the original investiga-
tors, dropouts were considered treatment failures. We would have
calculated the summary odds ratios and 95% confidence inter-
vals (CIs) (fixed-effect model) using the Cochrane Collaboration’s
statistical package (RevMan 5). Numbers needed to treat (NNT)
and their 95% CIs were to be calculated from the pooled OR and
its 95% CI for a specific baseline risk, which is the sum of all
the events in the control groups (in all trials) divided by the total
participant numbers in control groups in all trials using an online
calculator (Cates 2003).
For continuous outcomes, we recorded the mean change from
baseline for each group or mean post-treatment or post-inter-
vention values and standard deviation. Post-intervention standard
deviations were calculated, if not reported, from the reported
mean difference between groups (intervention and control) and
95% confidence intervals using the formulae detailed in Revman
(RevMan 5). If standard errors had been reported, we planned to
convert these to standard deviations. We then calculated a pooled
estimate of treatment effect by themean difference and 95%confi-
dence interval (fixed-effect model) again using RevMan (RevMan
5).
Unit of analysis issues
The identified cross-over study published only baseline data, thus
an analysis including the planned fixed-effect generic inverse vari-
ance (GIV) analysis in RevMan, summary weighted differences
and 95% CIs (RevMan 5) was not possible.
Dealing with missing data
The authors requested further information from the primary in-
vestigators of two studies (Brown 2005; Haworth 2004). We re-
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ceived a response from Haworth, but not from Brown; no addi-
tional information could be obtained.
Assessment of heterogeneity
Where possible we have combined study results with the same
outcome measure, described heterogeneity between study results
and used chi-squared test to determine any statistically significant
difference. Heterogeneity was considered to be significant with a
P value less than 0.10 (Deeks 2011). We also used the I2 statistic,
with heterogeneity categorised such that a value of under 25%
was considered low, around 50% moderate and over 75% a high
degree of heterogeneity (Higgins 2003).
Assessment of reporting biases
We had planned to assess publication bias using a funnel plot and
analysed the included trials for selective reporting.Wewere unable
to produce any funnel plots as there were insufficient studies i.e.
less than 10. However, asymmetry in a funnel plot may be due to
other reasons such as heterogeneity and reporting biases.
Data synthesis
We used a fixed-effect model in the analysis. A random-effects
model was planned if there had been concerns regarding statistical
heterogeneity (I2 higher than 50%).
Subgroup analysis and investigation of heterogeneity
The planned subgroup analyses (children and adults, formulation
of vitamin D, previous bowel resection, pancreatic insufficiency,
method of CF diagnosis, gender and latitude bands) to investigate
heterogeneity were not possible because there were too few trials
included in the review.
Sensitivity analysis
Sensitivity analysis either by random-effects model or by “treat-
ment received” was not possible because of the insufficient num-
ber of included studies in this review.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
Ten published abstracts or full papers to eight studies were identi-
fied via the electronic search as detailed in the Electronic searches
section. Two studies were excluded (Aris 2000; Gronowitz 2003),
three studies are listed as ’Studies awaiting classification’ (Hillman
2008; Judd 2008; Kumari 2009); thus this review consists of three
studies (Brown 2005; Haworth 2004; Popescu 1998), of which
only two had data that could be entered into the analysis (Haworth
2004; Popescu 1998).
Included studies
Three studies are included (Brown 2005; Haworth 2004; Popescu
1998); although only data from two were available (41 adults and
children with CF) (Haworth 2004; Popescu 1998).
One study was published as both an abstract and a full paper
(Haworth 2004); two studies have, as yet, been published as ab-
stracts only (Brown 2005; Popescu 1998). Both studies with avail-
able data were short term (one year or less) (Haworth 2004;
Popescu 1998), the third study reported only baseline data prior
to two years of calcitriol supplementation (Brown 2005).
The Haworth study was a 12-month trial in osteopenic (z score <
-1), pancreatic insufficient adults with CF (Haworth 2004). The
trial compared the effects of additional vitamin D (800 IU) and
calcium (1g) to placebo onBMDand biochemicalmarkers of bone
turnover; both groups continued standard vitamin D treatment
(900IU daily).
A second study had four arms comparing six months of supple-
mental vitamin D (1600 IU) alone, vitamin D (1600 IU) and
calcium (1g), calcium (1g) alone and placebo in “mildly affected
children with CF”; only the vitamin D and placebo arms were
included (Popescu 1998).
The data from the third study were not able to be included as only
baseline BMD and markers of bone turnover in pancreatic insuf-
ficient children and young adults prior to two years of calcitriol
supplementation (0.25 mcg if the participant weighed under 45
kg, 0.5 mcg if the participant weighed 45 kg and over) and some
narrative adverse event information were reported (Brown 2005).
Excluded studies
Two studies were excluded due to interventions not forming part
of this review - bisphosphate and ultraviolet (UV)B radiation (Aris
2000; Gronowitz 2003).
Risk of bias in included studies
Allocation
There were no details given on method of generation of alloca-
tion sequence or its concealment in any of the included studies,
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although one study does state that participants were randomised
by gender and age (8 to 10, 11 to 14, 15 to 18 years) to stratify for
pubertal status (Brown 2005). We therefore judged there to be an
unclear risk of bias for this for all included studies (Brown 2005;
Haworth 2004; Popescu 1998).
Blinding
Two studies do not mention blinding at all (Brown 2005; Popescu
1998), the third study is described as double-blind, but does not
give details of who was blinded (Haworth 2004). Therefore we
judged there to be an unclear risk of bias from blinding for all
studies (Brown 2005; Haworth 2004; Popescu 1998).
Incomplete outcome data
Nodata are available for any outcomes in one study (Brown 2005).
Data from the other abstract were also limited (Popescu 1998).
A further search did not yield any published papers subsequent
to the abstracts. No additional outcome data could be obtained
from the authors. In the final study, there was one withdrawal
due to pregnancy in the intervention group (Haworth 2004). It is
unclear if the data were removed from the baseline characteristics
published since summary data alone are given. Therefore we judge
there to be an unclear risk of bias for all three included studies
due to incomplete outcome data (Brown 2005; Haworth 2004;
Popescu 1998).
Selective reporting
In the Popescu study, data are reported after only 9 months of a
36-month study, we therefore judge this study to have a high risk
of selective reporting (Popescu 1998). We did not identify any
selective reporting in the other two included studies and judge
there to be a low risk of bias from this for these studies (Brown
2005; Haworth 2004).
Other potential sources of bias
We did not identify any other potential sources of bias in any of
the studies (Brown 2005; Haworth 2004; Popescu 1998).
Effects of interventions
No data could be combined as the studies presented results in
different formats. Thus sensitivity analyses, subgroup analyses or
assessment of heterogeneity could not be undertaken for this ver-
sion of the review.
Primary outcomes
1. Bone mineral density or Vitamin D-specific deficiency
outcomes
There was no available data on the primary outcome from any
study.
2. Growth and nutritional status (weight z score)
No study reports weight Z score (Brown 2005; Haworth 2004;
Popescu 1998).Two studies reported baseline BMI but did not
report either any follow up or end of intervention data or any
change in BMI (Brown 2005; Haworth 2004). Popescu reports
no growth or nutritional status measures (Popescu 1998).
Secondary outcomes
1. Other vitamin D-related deficiency disorders
a. fractures
This outcome was not reported in any of the included studies.
b. tetany
This outcome was not reported in any of the included studies.
c. rickets
This outcome was not reported in any of the included studies.
d. other radiological abnormality
This outcome was not reported in any of the included studies.
e. measured levels of calcium and vitamin D (25-
hydroxyvitamin D (25 (OH) D) or 1.25-dihydroxyvitamin D
(1.25 (OH) D))
One study (Haworth 2004) reported data on serum calciumwhich
showed no difference between groups (Analysis 1.1). Two studies
reported data for vitamin D (25 (OH) D), one at nine months
(Popescu 1998) and one at 12 months (Haworth 2004) and one
study reported data for vitamin D (1,25 (OH) D) at nine months
(Popescu 1998). We were able to combine the data for vitamin
D (25 (OH) D) and have presented all data in the meta-analysis,
but no significant differences between groups were reported. For
25 (OH) D, the mean difference between groups was -2.79 pg/
ml (95% confidence interval (CI) -7.25 to 1.6) (Analysis 1.2); for
1,25 (OH) D the mean difference was -3.50 pg/ml (95% CI -
22.51 to 15.510 (Analysis 1.3).
7Vitamin D supplementation for cystic fibrosis (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2. Respiratory outcomes
a. bronchiectasis severity control
This outcome was not reported in any of the included studies.
b. lung function indices
All three included studies reported lung function indices at base-
line only (Brown 2005; Haworth 2004; Popescu 1998).
c. proportions of participants who had respiratory
exacerbations or hospitalisations or both
This outcome was not reported in any of the included studies.
e. total number of hospitalised days
This outcome was not reported in any of the included studies.
f. other objective indices
This outcome was not reported in any of the included studies.
3. Quality of life
This outcome was not reported in any of the included studies.
4. Adverse events
Two studies did not report any adverse outcomes from either group
of participants (Haworth 2004; Popescu 1998). One of the ab-
stracts reported that two participants (one in each group) devel-
oped nephrolithiasis; furthermore one participant in the treatment
group developed mild hypercalcaemia and two participants in the
placebo group had hypercalciuria (Brown 2005). We could not
present this data in the analysis as we could not ascertain from the
abstract how many children were in each arm of the study.
5. Parathyroid hormone levels
Two studies reported on this outcome, but we were unable to
combine the data since one reported an absolute value at the end
of the study (Popescu 1998) and the other reported change in
parathyroid hormone levels after 12 months intervention (placebo
or supplementation) (Haworth 2004). Neither study reported any
significant difference between groups (Analysis 1.4; Analysis 1.5).
Post-hoc analysis
We include a post-hoc analysis ofmeanbonemineral density scores
(z scores) which were reported in two studies (Haworth 2004;
Popescu 1998). No data could be combined: Popescu reported
per cent change in whole body mineral bone content, mean dif-
ference (MD) -3.00% (95% CI -13.63 to 7.63) (Analysis 2.1)
and lumbar spine z score at nine months (six months of treat-
ment and a three-month washout period), MD -0.24 (95% CI
-1.27 to 0.79) (Analysis 2.2) (Popescu 1998); and Haworth re-
ported per cent change in bone mineral density after 12 months
of treatment measured in the lumbar spine, MD 1.90 (95% CI -
0.90 to 4.70) ()Analysis 2.3; the hip, MD 0.70 (95% CI -2.20 to
3.60) (Analysis 2.4); and the distal forearm, MD 1.70 (95% CI -
2.20 to 5.60 (Analysis 2.5) (Haworth 2004). For all the available
outcomes, there was no significant difference between the groups.
Bone mineral density z score do not meet the primary bone min-
eral density outcome measures of this review, but are an objective
and reproducible assessment of intervention effect (Analysis 2.1;
Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis 2.5).
D I S C U S S I O N
Daily vitamin D supplementation is almost universally recom-
mended for people with CF who are pancreatic insufficient
(Borowitz 2002; Sinaasappel 2002; UK CF Trust 2007). In this
review we attempted to evaluate the effect of vitamin D supple-
mentation compared with placebo on the frequency of vitamin
D deficiency, including BMD, growth and nutrition, respiratory
status, biochemical markers of bone metabolism in children and
adults with CF. However, it is unfortunate that there were only
three small controlled studies that have examined this comparison
and only two which have published any post-treatment data. Also
the studies used different formulations of vitamin D.
Summary of main results
There was no clear benefit or harm identified with short-term vi-
tamin D supplementation compared to placebo in the 41 people
with CF completing the period of intervention in the two studies
with available data (Haworth 2004; Popescu 1998). This number
excludes one study which has only been published as an abstract
and only contains baseline data and narrative information on ad-
verse events (Brown 2005). This study reports adverse events in
6 out of 54 participants; nephrolithiasis occurred in two (placebo
and calcitriol), mild asymptomatic hypercalcaemia in one receiv-
ing calcitriol, hypercalciuria in two receiving placebo, and hyper-
phosphataemia in one receiving placebo (Brown 2005). No ad-
verse events occurred in the full publication included in this review
(Haworth 2004).
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Overall completeness and applicability of
evidence
The three studies meeting inclusion criteria provided data for as-
sessment of the efficacy of short-term (up to 12 months) vitamin
D supplementation on BMD in a small number of children and
adults with CF. There were no data on the effects of supplemen-
tation on growth and nutrition. No conclusions about the longer
term effects of vitamin D supplementation, either beneficial or
harmful, can be drawn due to the short-term nature of supple-
mentation and follow up. All participants in the Haworth study
continued the centre’s routine vitamin D supplement of 900 IU
daily (Haworth 2004). This was in keeping with the UK guide-
lines (UK CF Trust 2007) and may not be standard practice in
all centres. Many of the secondary outcomes (effect of vitamin D
supplementation on the frequency of clinical markers of vitamin
D deficiency, respiratory outcomes and quality of life) were not
assessable from data in any study which limits the external validity
of the outcomes. No study provided information to address poten-
tial confounders during the study period, including measures of
pancreatic sufficiency or adequacy of pancreatic enzyme replace-
ment in pancreatic-insufficient participants; the season, latitude
and ethnicity of participants (which will directly impact on 25-
OHD levels and thus BMD); the amount of weight-bearing activ-
ity; respiratory status; or frequency of illness. These factors limit
the generalisability of these results to other CF populations.
Quality of the evidence
This review includes only three small studies of short term vitamin
DsupplementationwithBMD(either as percent change or z score)
the only consistently reported primary outcomemeasure. The lack
of information regardingmethods used todiagnoseCF; respiratory
and disease status, growth and nutrition during the study; and the
adequacy of exocrine pancreatic function or enzyme replacement
restrict the generalisation of each study’s findings to the general CF
population. All relevant studies are likely to have been identified by
our searchmethods. Twopaperswere abstracts and thus assessment
was limited (Brown 2005; Popescu 1998).
Potential biases in the review process
The two authors’ independent review of included studies and data
extraction minimised the potential for additional bias beyond that
detailed in the risk of bias tables. Neither of the authors have any
conflict of interest.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a lack of published data on the effect of vitamin D supple-
mentation, including benefits and adverse effects, in people with
CF. The data, which are limited by very small numbers, showed no
benefit or harm in the supplemented group. Until further studies
are available, adherence to relevant guidelines on supplementation
with vitamin D and calcium, such as the UK guidelines (UK CF
Trust 2007), should be considered. Toxicity is an uncommon oc-
currence in the small number of published randomised, controlled
studies of vitamin D supplementation. Further randomised con-
trolled trials are clearly required.
Also it is biologically plausible that currently, with improved pan-
creatic replacement therapies and attention tomacro nutrition and
caloric supplements, themajority of people with CF are vitaminD
sufficient and may not require daily vitamin D supplementation.
Daily supplementation in these situations at best causes no harm,
but adds a further burden to the daily medical regimen of people
with CF.
Implications for research
The available data suggest theCFpopulationhave lower vitaminD
levels and bone mineral density than age and gender-matched un-
affected individuals, but this is likely to be multifactorial (e.g. mal-
absorption, chronic illness, pubertal delay, reduced activity partic-
ularly weight bearing activity and medications impairing physio-
logical bone remodeling) which may not necessarily be overcome
by supplementation. Parallel randomised controlled trials of vita-
min D supplementation in CF are required and should take into
account the effects of pubertal stage, latitude and season, ethnicity,
severity of lung disease and adequacy of enzyme replacement in
pancreatic-insufficient patients. Future studies may also need to
take broad genetic mutations groups (such as 1508 or not) into
account although this likely increases the complexity of the study.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brown 2005
Methods Randomised, parallel, double-blind, placebo-controlled trial
Participants 54 (31 male, 23 female) pancreatic insufficient children and young adults with CF. Age
range 8 -18 years (mean age 12.1 (SD 3.1) years), mean (SD) BMI 18.1 (2.9) kg/m2,
mean (SD) FEV1 80 (20) % predicted, range 36 - 129%.
Numbers in intervention and control groups not stated.
31 (18 male, 13 female) healthy sibling or community controls mean age 11.7 (2.9)
years were recruited to assess BMD normative data
Interventions Participants randomised to 2 years supplementation with oral calcitriol (1,25 (OH)2D
0.25 mcg daily if under 45 kg, 0.5 mcg daily if weight was 45 kg or above) or placebo
All participants continued their usual calcium (500 mg daily) and vitamin D (dose and
preparation not specified)
Outcomes Data only published for baseline/pre-intervention characteristics and some adverse events
BMD (whole body, lumbar spine, hip and radius; method not specified) measured at
baseline, 6, 12 and 24 months
Serum and urine chemistry (including calcium and phosphate), vitamin D and bone
markers (not otherwise specified) measured at baseline, 3, 6, 12-18 and 24 months
Frequency of supplementation related complications.
Bone age at baseline, pubertal status and dietary intake recorded
Notes Abstract of poster presented at 19th Annual North American CF Conference 2005
No reply to email requesting further data.
No reference to season, latitude or compliance.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not reported but
states that participants were randomised by
gender and age (8-10, 11-14,15-18 yrs) to
stratify for pubertal status
Healthy siblings and community subjects
recruited to assess normative BMD data
Allocation concealment (selection bias) Unclear risk No method reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No method reported.
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Brown 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Baseline/pre-intervention data only. Num-
bers in each group not reported
32/54 reported to complete study; only 4
withdrawals accounted for
Selective reporting (reporting bias) Low risk All outcomes are recorded.
Other bias Unclear risk Follow up data not published.
No description of CF diagnosis method.
No reports of compliance with enzyme re-
placement or study medications
No season or latitude specified.
Haworth 2004
Methods Parallel, randomised, double-blind, placebo-controlled study over 12 months
Single centre (Manchester adult CF unit).
Participants 31 pancreatic-insufficient and osteopenic adults (over 18 years) with CF (confirmation
of CF diagnosis by genetic testing).
No definition of pancreatic insufficiency.
BMD z score less than -1 (lumbar spine, proximal femur or distal forearm)
16 in intervention group (9 female, 7 males). Mean age 29.4 years; mean FEV1 66.1%
predicted; mean BMI 23.0kg/m2).
15 in control group (7 females, 8 males)Mean age 25.9 years; mean FEV1 60.9% ; mean
BMI 21.1kg/m2.
Interventions Supplementation with 1g calcium and 800 IU vitamin D daily (Calichew D3 forte 1
tablet twice daily) or placebo for 12 months
All participants continued standard daily vitamin D supplements (900 IU)
Outcomes Outcomes measured at baseline and after 12 months.
BMD (DXA lumbar spine and total hip, peripheral CT distal forearm)
Biochemical markers of bone turnover (25-OHD, PTH, osteocalcin, bone specific al-
kaline phosphatase, urinary crosslinks)
Notes 8 participants in each intervention had corticosteroids during study period, but dose not
reported. Compliance - treatment group 3.1 days/week, controls 3.7 days/week
Prof Howarth was contacted and replied but was unable to provide any unpublished
data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details of randomisation.
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Haworth 2004 (Continued)
Allocation concealment (selection bias) Unclear risk No description of allocation concealment.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Method notes double blinding although no
details of blinding or method used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 study withdrawal due to pregnancy in
intervention group, although this wasn’t a
specified exclusion criteria. Thus good fol-
low-up rate (97%)
All others enrolled completed study period.
Selective reporting (reporting bias) Low risk All defined outcomes are reported.
Other bias Unclear risk All subjects were participants of a longitu-
dinal BMD study preceding this study
Only 31/55 eligible participants enrolled,
no specifics given for those who declined to
participate
Popescu 1998
Methods Double-blind, randomised, cross-over study.
Participants 22 children with CF (mean 9.3 years, range 6.1 - 12.2 years). No disease status indicators
reported - authors comment that all were “mildly affected”
Interventions Supplementation with 1g calcium, 1600 IU vitamin D, 1g calcium and 1600 IU vitamin
D and placebo each for 6 months with a 3-month washout period between interventions
Outcomes Outcomes reported at baseline and at 9 months (after 6 months of intervention and
3 month washout period): BMD (lumbar spine, femoral neck, distal radius and whole
body; method not described)
Outcomes reported at baseline and at 6 months of supplementation: serum and urine
chemistry, 25-OHD, 1,25-(OH)2D, PTH, bone turnover markers (osteocalcin, bone
specific alkaline phosphatase)
Notes Abstract of poster presented at 12th annual North American CF conference
No inclusion criteria, no numbers of eligible participants stated
No reporting of method of CF diagnosis, rates of pancreatic insufficiency, nutrition or
growth parameters
Abstract was more than 10 years ago and a search using authors’ name did not reveal full
publication. We could not find authors and hence not contacted
Risk of bias
Bias Authors’ judgement Support for judgement
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Popescu 1998 (Continued)
Random sequence generation (selection
bias)
Unclear risk No description given.
Allocation concealment (selection bias) Unclear risk No description given.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All data inmethods are reported; no report-
ing of number of children enrolled or eli-
gible
Selective reporting (reporting bias) High risk Data after only 9 months of a 36-month
study.
Other bias Unclear risk No funding source identified. No report-
ing of disease severity or respiratory/other
confounding illnesses or nutritional status
BMD: bone mineral density
BMI: body mass index
CF: cystic fibrosis
CT: computerised tomography
DXA: dual energy X-ray absorptiometry
FEV1: forced expiratory volume at one second
g: gram
IU: international units
PTH: parathyroid hormone
SD: standard deviation
25 (OH) D: 25-hydroxyvitamin D
1,25(OH)2D: 1,25-dihydroxyvitamin D
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aris 2000 Intervention (pamidronate, a bisphosphonate) does not meet review inclusion criteria
Gronowitz 2003 Intervention (Ultraviolet B radiation) does not meet review inclusion criteria
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Characteristics of studies awaiting assessment [ordered by study ID]
Hillman 2008
Methods Double-blinded randomized cross-over trial with 4 arms. Single centre in USA
Participants 15 children aged 7 to 13, remained on standard medication (including pancreatic enzymes and ADEK vitamins).
Children on oral or glucocorticoids were excluded
Interventions 4x 6 month treatments (including placebo) with 3-month washout period between each
Placebo vs calcium (1g) vs vitamin D (1,600 IU) vs calcium (1g) plus vitamin D (1,600 IU)
Outcomes Blood and urine collected at beginning and end of each treatment
DXA performed at baseline, the beginning of each period and at 36 months (9 months between DXA - 6 month
treatment plus washout)
Calcium absorption at end of each period.
Also, serum calcium, phosphorus, magnesium, parathyroid hormone, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin
D, osteocalcin, bone alkaline phosphatase, tartrate resistant acid phosphatase, urine calcium/creatinine ratio
Notes
Judd 2008
Methods Randomized (in blocks of 6) cross-over trial with 3 arms. Single centre in USA
Participants 30 adults (16 - 70 years old) with CF and with screening 25-hydroxyvitamin D levels between 10 nd 40 ng/ml
randomized; 18 completed trial
Exclusion criteria: renal or hepatic disease, history of skin cancer, treatment with more than 2000 IU of vitamin D
or prednisone or a history of more than 6 hospitalizations in past year
Interventions Treatment 1: cholecalciferol 50,000 IU once a week for 12 weeks
Treatment 2: ergocalciferol 50,000 IU once a week for 12 weeks
Treatment 3: UV light therapy given for 3 - 10 mins 5 times per week for 12 weeks
Outcomes
Notes
Kumari 2009
Methods Randomised (in blocks of 6) to intervention or placebo
Participants 30 adults (age over 18 years old) with CF and hospitalised with acute respiratory exacerbation
Interventions 250,000 IU vitamin D3 or placebo as single dose within 48 hours of hospital admission
Exclusion criteria: current therapy with high dose vitamin D (over 2000 IU daily) or admission for serious terminal
illness
Outcomes Blood collected for 25-hydroxyvitamin D level at randomization and hospital discharge, results reported for the first
12 of 30 enrolled participants
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Kumari 2009 (Continued)
Notes Abstract only. Trial completed, paper submitted for editorial review and consideration of publication
CF: cystic fibrosis
IU: international units
UV: ultra-violet
vs: versus
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